The Role of Irreversible EGFR Inhibitors in the Treatment of Non-Small Cell Lung Cancer: Overcoming Resistance to Reversible EGFR Inhibitors

被引：30

作者：

Belani, Chandra P. ^{[1
]}

机构：

[1] Penn State Milton S Hershey Med Ctr, Penn State Hershey Canc Inst, Hershey, PA 17033 USA

来源：

CANCER INVESTIGATION | 2010年 / 28卷 / 04期

关键词：

Non-small cell lung cancer; Epidermal growth factor receptor; HER2; Irreversible tyrosine kinase inhibitors-BIBW 2992; HKI-272; PF00299804; GROWTH-FACTOR-RECEPTOR; TYROSINE KINASE INHIBITOR; I DOSE-ESCALATION; PREVIOUSLY TREATED PATIENTS; PAN-ERBB INHIBITOR; ACQUIRED-RESISTANCE; PHASE-I; EGFR/HER2; INHIBITOR; CLINICAL ACTIVITY; T790M MUTATIONS;

D O I：

10.3109/07357901003631072

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Reversible epidermal growth factor receptor tyrosine kinase inhibitors are often used for the treatment of non-small cell lung cancer following failure of cytotoxic chemotherapy. While these agents are active in a subset of patients, most develop resistance and progress within the course of 1 year. In nearly half of the cases, acquired resistance is caused by a secondary epidermal growth factor receptor T790M mutation. Irreversible epidermal growth factor receptor tyrosine kinase inhibitors are an emerging class of agents that may have the potential to overcome and prevent the emergence of such mutation-related resistance.

引用

页码：413 / 423

页数：11

共 84 条

[1]

AGUS D, 2006, 42 ANN M AM SOC CLIN

[2]

[Anonymous], NCCN CLIN PRACT GUID

[3]

[Anonymous], P AM SOC CLIN ONCOL

[4] Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor - Mutant lung adenocarcinomas with acquired resistance to kinase inhibitors [J].

Balak, Marissa N. ;

Gong, Yixuan ;

Riely, Gregory J. ;

Somwar, Romel ;

Li, Allan R. ;

Zakowski, Maureen F. ;

Chiang, Anne ;

Yang, Guangli ;

Ouerfelli, Ouathek ;

Kris, Mark G. ;

Ladanyi, Marc ;

Miller, Vincent A. ;

Pao, William .

CLINICAL CANCER RESEARCH, 2006, 12 (21) :6494-6501

[5] Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions [J].

Barr, Sharon ;

Thomson, Stuart ;

Buck, Elizabeth ;

Russo, Suzanne ;

Petti, Filippo ;

Sujka-Kwok, Izabela ;

Eyzaguirre, Alexandra ;

Rosenfeld-Franklin, Maryland ;

Gibson, Neil W. ;

Miglarese, Mark ;

Epstein, David ;

Iwata, Kenneth K. ;

Haley, John D. .

CLINICAL & EXPERIMENTAL METASTASIS, 2008, 25 (06) :685-693

[6] MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib [J].

Bean, James ;

Brennan, Cameron ;

Shih, Jin-Yuan ;

Riely, Gregory ;

Viale, Agnes ;

Wang, Lu ;

Chitale, Dhananjay ;

Motoi, Noriko ;

Szoke, Janos ;

Broderick, Stephen ;

Balak, Marissa ;

Chang, Wen-Cheng ;

Yu, Chong-Jen ;

Gazdar, Adi ;

Pass, Harvey ;

Rusch, Valerie ;

Gerald, William ;

Huang, Shiu-Feng ;

Yang, Pan-Chyr ;

Miller, Vincent ;

Ladany, Marc ;

Yang, Chih-Hsin ;

Pao, William .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (52) :20932-20937

[7] Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: Molecular analysis of the IDEAL/INTACT gefitinib trials [J].

Bell, DW ;

Lynch, TJ ;

Haserlat, SM ;

Harris, PL ;

Okimoto, RA ;

Brannigan, BW ;

Sgroi, DC ;

Muir, B ;

Riemenschneider, MJ ;

Iacona, RB ;

Krebs, AD ;

Johnson, DH ;

Giaccone, G ;

Herbst, RS ;

Manegold, C ;

Fukuoka, M ;

Kris, MG ;

Baselga, J ;

Ochs, JS ;

Haber, DA .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (31) :8081-8092

[8] Establishment and Characterization of a Model of Acquired Resistance to Epidermal Growth Factor Receptor Targeting Agents in Human Cancer Cells [J].

Benavente, Sergio ;

Huang, Shyhmin ;

Armstrong, Eric A. ;

Chi, Alexander ;

Hsu, Kun-Tai ;

Wheeler, Deric L. ;

Harari, Paul M. .

CLINICAL CANCER RESEARCH, 2009, 15 (05) :1585-1592

[9] Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors [J].

Bianco, R ;

Shin, I ;

Ritter, CA ;

Yakes, FM ;

Basso, A ;

Rosen, N ;

Tsurutani, J ;

Dennis, PA ;

Mills, GB ;

Arteaga, CL .

ONCOGENE, 2003, 22 (18) :2812-2822

[10]

Brabender J, 2001, CLIN CANCER RES, V7, P1850

← 1 2 3 4 5 6 7 8 9 →